MLTX vs NKTR โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MLTX Captures Institutional Edge (3โ1 Pillars ยท 4โ6 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while NKTR counters with relative strength in Valuation. Fundamentally, MLTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus NKTR at 34.0x Forward P/E and -239.3% operating margin (-9.3% YoY). In options structure, MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against NKTR sits in BREAKDOWN (5th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MLTX | NKTR | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.1B | $1.3B | Larger Scale | NKTR |
| Trailing P/E Ratio Valuation | N/M | 34.0x | Lower Multiple | NKTR |
| Forward P/E Ratio Valuation | N/M | 34.0x | Lower Multiple | NKTR |
| Revenue Growth (YoY) Growth | +0.0% | -9.3% | Higher Growth | MLTX |
| Operating Margin (TTM) Profitability | 0.0% | -239.3% | Higher Margin | MLTX |
| Net Profit Margin Profitability | 0.0% | -287.8% | Higher Margin | MLTX |
| Return on Equity (ROE) Capital Efficiency | -81.5% | -35.8% | Higher ROE | NKTR |
| 52-Week Range Position Momentum | 17% ($9โ$23) | 4% ($33โ$109) | Stronger Trend | MLTX |
| Beta / 30D Volatility Risk Regime | 1.61ฮฒ ยท 90% Vol | 1.10ฮฒ ยท 48% Vol | Lower Realized Risk | NKTR |
| Unified Institutional Score Composite Signal | 38.3 / 100 (SELL) | 61.1 / 100 (BUY) | Higher Composite | NKTR |